+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Managing the underestimated risk of statin-associated myopathy

Managing the underestimated risk of statin-associated myopathy

International Journal of Cardiology 159(3): 169-176

In clinical practice 5-10% of patients receiving statins develop myopathy, a side effect that had been systematically underestimated in the randomized controlled trials with statins. The most common manifestation of myopathy is muscle pain (usually symmetrical, involving proximal muscles) without creatinine kinase (CK) elevation or less frequently with mild CK elevation. Clinically significant rhabdomyolysis (muscle symptoms with CK elevation >10 times the upper limit of normal and with creatinine elevation) is extremely rare. Myopathy complicates the use of all statins (class effect) and is dose-dependent. The pathophysiologic mechanism of statin-associated myopathy is unknown and probably multifactorial. The risk of statin-associated myopathy can be minimized by identifying vulnerable patients (i.e. patients with impaired renal or liver function, advanced age, hypothyroidism, etc.) and/or by eliminating-avoiding statin interactions with specific drugs (cytochrome P-450 3A4 inhibitors, gemfibrozil, etc.). In symptomatic patients, the severity of symptoms, the magnitude of CK elevation and the risk/benefit ratio of statin continuation should be considered before statin treatment is discontinued. Potential strategies are the use of the same statin at a lower dose and if symptoms recur the initiation of fluvastatin XL 80 mg daily or rosuvastatin intermittently in low dose (5-10mg), combined usually with ezetimibe 10mg daily. Failure of these approaches necessitates the use of non-statin lipid lowering drugs (ezetimibe, colesevelam). In order to provide evidence based recommendations for the appropriate management of statin-intolerant patients we need randomized clinical trials directly comparing the myopathic potential of different lipid-lowering medications at comparable doses.

(PDF emailed within 0-6 h: $19.90)

Accession: 036168518

Download citation: RISBibTeXText

PMID: 21813193

DOI: 10.1016/j.ijcard.2011.07.048

Related references

Managing statin myopathy. Endocrinology and Metabolism Clinics of North America 38(1): 121-136, 2009

Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. Plos One 3(6): E2522-E2522, 2008

Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin. Molecular Diagnosis & Therapy 21(1): 95-105, 2016

Economic Evaluation Of A Pharmacogenomic Test For Statin-Induced Myopathy In Cardiovascular High-Risk Patients Initiating A Statin. Value in Health 18(7): A396-A396, 2015

Large copy-number variations in patients with statin-associated myopathy affecting statin myopathy-related loci. Physiological Research (): -, 2016

Statin discontinuation: an underestimated risk?. Current Medical Research and Opinion 24(11): 3059-3062, 2008

Statin-related muscle complaints: an underestimated risk. Cardiovascular Drugs and Therapy 19(6): 379-381, 2006

Risk for myopathy with statin therapy in high-risk patients. Archives of Internal Medicine 163(5): 553-564, 2003

Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Safety 33(3): 171-187, 2010

Risk of Daptomycin Associated Myopathy with Concomitant Statin Use. Clinical Infectious Diseases 2019, 2019

Statin myopathy: incidence, risk factors, and pathophysiology. Current Atherosclerosis Reports 9(5): 389-396, 2007

Statin Coadministration Increases the Risk of Daptomycin-Associated Myopathy. Clinical Infectious Diseases, 2018

Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin. American Journal of Medicine 130(5): 583-587, 2017

Fusidic Acid: A Neglected Risk Factor for Statin-Associated Myopathy. Clinical Medicine Insights. Cardiology 12: 1179546818815162-1179546818815162, 2019

Vitamin D deficiency, statin-related myopathy and other links with vascular risk. Current Medical Research and Opinion 27(9): 1691-1692, 2011